EMA Authorised: Infanrix Hexa (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);hepatitis B surface antigen;poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain));Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.

View source ↗

Summary

The European Medicines Agency authorised Infanrix Hexa, a hexavalent vaccine that combines diphtheria, tetanus, pertussis, hepatitis B, poliovirus, and Haemophi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Meningitis
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix Hexa (DTPa-HBV-IPV/Hib)

Snippet

Status: Authorised. Therapeutic area: Hepatitis B;Tetanus;Immunization;Meningitis, Haemophilus;Whooping Cough;Poliomyelitis;Diphtheria. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 12/02/2026